Related Experiment Videos
Verapamil does not alter platelet function in patients with recent myocardial infarction
Thrombosis Research
|November 15, 1983
Summary
Verapamil, a calcium antagonist, did not affect platelet function in patients with ischemic heart disease. This randomized trial found no changes in bleeding time or platelet aggregation after three months of verapamil treatment.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Conflicting reports exist regarding verapamil's influence on platelet function.
- Platelet function is crucial in ischemic heart disease pathogenesis.
Purpose of the Study:
- To investigate the effect of verapamil on platelet function in patients with acute myocardial infarction.
Main Methods:
- A randomized, double-blind trial was conducted.
- 52 patients with acute myocardial infarction received verapamil 120 mg orally three times daily for three months.
Main Results:
- No significant alterations were observed in cutaneous bleeding time.
- Platelet aggregate ratio remained unchanged.
- Platelet aggregation induced by ADP or collagen was not affected.
Conclusions:
- Therapeutic doses of verapamil do not appear to impact platelet function in patients suffering from ischemic heart disease.